Palvella reports FY2025 net loss $41.7M; Phase 3 SELVA success paves path to NDA in H2 2026

PALVELLA THERAPEUTICS, INC.

2026-Q1 EPS reported -$1.20 vs consensus -$0.95 ▼ miss (-26.2%)

Net loss $41.7M ($3.71 per share) vs $17.4M ($7.83) in FY2024; R&D $22.8M, G&A $15.8M.
Cash $58M at Dec 31; pro forma cash ~$274M after $230M oversubscribed equity offering closed Feb 2026.
Phase 3 SELVA for microcystic LMs met primary endpoint (p<0.001); NDA submission on track for H2 2026.
Phase 3 trial for cutaneous venous malformations planned H2 2026; Phase 2 for angiokeratomas in Q2 2026.
Company to announce fourth QTORIN rapamycin indication and third platform product in H2 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PALVELLA THERAPEUTICS, INC. reported financial results for full year ending December 31, 2025.

Period: full year ending December 31, 2025
Result: reported results

Exact text from the filing

On March 31, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

PALVELLA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-133332

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.